APA (7th ed.) Citation

A, G., E, B., A, D. C., O, N., R, W., A, F., . . . N, H. (2024). Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET. Annals of oncology : official journal of the European Society for Medical Oncology, 35(6), 549. https://doi.org/10.1016/j.annonc.2024.02.007

Chicago Style (17th ed.) Citation

A, Gennari, et al. "Early Prediction of Endocrine Responsiveness in ER+/HER2-negative Metastatic Breast Cancer (MBC): Pilot Study with 18F-fluoroestradiol (18F-FES) CT/PET." Annals of Oncology : Official Journal of the European Society for Medical Oncology 35, no. 6 (2024): 549. https://doi.org/10.1016/j.annonc.2024.02.007.

MLA (9th ed.) Citation

A, Gennari, et al. "Early Prediction of Endocrine Responsiveness in ER+/HER2-negative Metastatic Breast Cancer (MBC): Pilot Study with 18F-fluoroestradiol (18F-FES) CT/PET." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 35, no. 6, 2024, p. 549, https://doi.org/10.1016/j.annonc.2024.02.007.